Teriparatide for postmenopausal osteoporosis
Once-daily injection of parathyroid hormone (1-34), a peptide that stimulates bone formation, reduced new vertebral fractures in postmenopausal women with osteoporosis.
What the study found
Once-daily injections of parathyroid hormone or its amino-terminal fragments increase bone formation and bone mass, but their effect on fractures had been unknown. In this trial (New England Journal of Medicine, 2001), 1,637 postmenopausal women with prior vertebral fractures were randomly assigned to receive 20 or 40 micrograms of parathyroid hormone (1-34) — later marketed as teriparatide — or placebo, injected under the skin daily for a median of about 21 months. New vertebral fractures occurred in 14 percent of the placebo group versus 5 percent and 4 percent of the two hormone groups, and bone mineral density rose. This describes what the trial measured; it is not advice, and nothing here recommends any medicine.
The peptide angle
Most osteoporosis drugs slow bone loss. Parathyroid hormone (1-34) is a peptide fragment that, given intermittently, does the opposite — it stimulates bone-building cells to form new bone. Delivering it as a short daily injection mimics a pulse of the natural hormone, a different strategy from continuous exposure, which can instead break bone down.
Analysis — the pattern
This fits a broader theme (analysis, not a single-study claim): peptides derived from the body's own hormones can be engineered into drugs, and the timing of exposure can flip their effect. Anabolic (bone-building) agents opened a distinct class alongside anti-resorptive drugs.
What is still uncertain
Trials report averages, not individual outcomes. Effects on non-vertebral fractures, how long treatment can safely continue, what happens after stopping, and long-term safety were all still being studied.